Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...

Samsung Bioepis held an awards ceremony for the 'Research Notebook Competition' at Yonsei University's Sinchon campus and presented excellent plaques and a scholarship worth 10 million won to ...

South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...

Korean firms seek US FDA approval for new anticancer drugs and biosimilars Korean pharmaceutical companies renewed their ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

INR:1526. win fortune slots EU approves dolutegravir dispersible tablets for the treatment of pediatric patients aged ≥ 4 weeks and ≥ 3 kg Biogen acquires r ...

INR:1994. top casino in world How to build a medical insurance policy that adapts to the development of primary medical care? The National Medical Insurance A ...

and Samsung Bioepis, and managed by Samsung Venture Investment Corporation. Established in 2021 and worth KRW 240 billion, the fund has invested in biotech companies with promising technologies.

Amgen Canada Inc., 2024 FC 1137, the Federal Court partly granted the motion. The court scheduled Samsung Bioepis Co., Ltd. v Janssen Biotech, Inc., T-2324-23 on Jan. 8, Wednesday. The plaintiff in ...